Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Research & Development: 2012-2023

Historic Research & Development for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to $1.2 million.

  • RedHill Biopharma's Research & Development fell 15.29% to $1.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $5.1 million, marking a year-over-year decrease of 68.71%. This contributed to the annual value of $1.6 million for FY2024, which is 54.99% down from last year.
  • Per RedHill Biopharma's latest filing, its Research & Development stood at $1.2 million for Q2 2023, which was up 15.04% from $1.1 million recorded in Q1 2023.
  • RedHill Biopharma's 5-year Research & Development high stood at $10.3 million for Q2 2021, and its period low was $1.1 million during Q1 2023.
  • In the last 3 years, RedHill Biopharma's Research & Development had a median value of $2.3 million in 2022 and averaged $3.9 million.
  • In the last 5 years, RedHill Biopharma's Research & Development soared by 221.34% in 2021 and then tumbled by 85.75% in 2022.
  • Over the past 5 years, RedHill Biopharma's Research & Development (Quarterly) stood at $2.3 million in 2019, then spiked by 171.92% to $6.2 million in 2020, then fell by 5.19% to $5.9 million in 2021, then tumbled by 80.69% to $1.1 million in 2022, then declined by 15.29% to $1.2 million in 2023.
  • Its Research & Development stands at $1.2 million for Q2 2023, versus $1.1 million for Q1 2023 and $1.1 million for Q4 2022.